Krystal Biotech (NASDAQ:KRYS) Trading 2.7% Higher on Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS)’s share price traded up 2.7% during trading on Wednesday after HC Wainwright raised their price target on the stock from $200.00 to $221.00. HC Wainwright currently has a buy rating on the stock. Krystal Biotech traded as high as $203.60 and last traded at $203.57. 76,820 shares were traded during trading, a decline of 79% from the average session volume of 361,466 shares. The stock had previously closed at $198.22.

A number of other research firms have also recently issued reports on KRYS. Citigroup restated a “neutral” rating and set a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a report on Tuesday, August 6th. Evercore ISI boosted their target price on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Finally, Chardan Capital raised their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $190.22.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 14.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Krystal Biotech in the 2nd quarter worth about $555,000. Creative Planning increased its holdings in Krystal Biotech by 21.6% during the 2nd quarter. Creative Planning now owns 3,484 shares of the company’s stock worth $640,000 after purchasing an additional 618 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Krystal Biotech in the second quarter worth approximately $340,000. Driehaus Capital Management LLC raised its stake in shares of Krystal Biotech by 7.8% in the second quarter. Driehaus Capital Management LLC now owns 118,746 shares of the company’s stock worth $21,807,000 after purchasing an additional 8,547 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C bought a new position in shares of Krystal Biotech in the second quarter valued at approximately $295,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 4.3 %

The company has a 50-day moving average of $193.63 and a 200-day moving average of $172.84. The company has a market cap of $5.58 billion, a PE ratio of 104.40 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The company had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. During the same quarter last year, the business posted ($1.25) earnings per share. Krystal Biotech’s revenue was up 70283900.0% on a year-over-year basis. As a group, equities analysts predict that Krystal Biotech, Inc. will post 2 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).